|
This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or
standards of non-Merck sources.
Pronunciation
(a moks i SIL in)
Generic Available (U.S.)
Yes: Excludes extended-release formulation
Index Terms
U.S. Brand Names
Canadian Brand Names
Pharmacologic Category
Pharmacologic Category Synonyms
Use: Labeled Indications
Treatment of otitis media, sinusitis, and infections caused by susceptible organisms involving the upper and lower respiratory tract, skin, and urinary tract; prophylaxis of infective endocarditis in patients undergoing surgical or dental procedures; as part of a multidrug regimen for H. pylori eradication
Use: Dental
Antibiotic for standard prophylactic regimen for dental patients who are at risk for infective endocarditis; prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia; antibiotic used to treat orofacial infections
Use: Unlabeled/Investigational
Postexposure prophylaxis for anthrax exposure with documented susceptible organisms
Pregnancy Risk Factor
B
Pregnancy Considerations
Adverse events have not been observed in animal studies; therefore, amoxicillin is classified as pregnancy category B. There is no documented increased risk of adverse pregnancy outcome or teratogenic effects caused by amoxicillin. It is the drug of choice for the treatment of chlamydial infections in pregnancy and for anthrax prophylaxis when penicillin susceptibility is documented.Due to pregnancy-induced physiologic changes, amoxicillin clearance is increased during pregnancy resulting in lower concentrations and smaller AUCs. Oral ampicillin-class antibiotics are poorly-absorbed during labor.
Lactation
Enters breast milk/use caution (AAP rates “compatible”; AAP 2001 update pending)
Breast-Feeding Considerations
Very small amounts of amoxicillin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering amoxicillin to nursing women. Nondose-related effects could include modification of bowel flora and allergic sensitization of the infant.
Contraindications
Hypersensitivity to amoxicillin, penicillin, other beta-lactams, or any component of the formulation
Warnings/Precautions
Concerns related to adverse effects:
• Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
Disease-related concerns:
• Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients.
• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. In addition, use of certain dosage forms (eg, extended release 775 mg tablet and immediate release 875 mg tablet) should be avoided in patients with Clcr <30 mL/minute or patients requiring hemodialysis.
Dosage form specific issues:
• Phenylalanine: Chewable tablets contain phenylalanine.
Adverse Reactions
Frequency not defined.
Central nervous system: Agitation, anxiety, behavioral changes, confusion, dizziness, headache, hyperactivity (reversible), insomnia, seizure
Dermatologic: Acute exanthematous pustulosis, erythematous maculopapular rash, erythema multiforme, exfoliative dermatitis, hypersensitivity vasculitis, mucocutaneous candidiasis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria
Gastrointestinal: Black hairy tongue, diarrhea, hemorrhagic colitis, nausea, pseudomembranous colitis, tooth discoloration (brown, yellow, or gray; rare), vomiting
Hematologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, leukopenia,thrombocytopenia, thrombocytopenia purpura
Hepatic: Acute cytolytic hepatitis, ALT increased, AST increased, cholestatic jaundice, hepatic cholestasis
Renal: Crystalluria
Miscellaneous: Anaphylaxis, serum sickness-like reaction
Drug Interactions
Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin. Risk C: Monitor therapy
BCG: Antibiotics may diminish the therapeutic effect of BCG. Risk X: Avoid combination
Fusidic Acid: May diminish the therapeutic effect of Penicillins. Risk D: Consider therapy modification
Methotrexate: Penicillins may decrease the excretion of Methotrexate. Risk C: Monitor therapy
Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. Risk C: Monitor therapy
Probenecid: May increase the serum concentration of Penicillins. Risk C: Monitor therapy
Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins. Risk D: Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents. Risk D: Consider therapy modification
Storage
Amoxil®: Oral suspension remains stable for 14 days at room temperature or if refrigerated (refrigeration preferred). Unit-dose antibiotic oral syringes are stable at room temperature for at least 72 hours (Tu, 1988).
Moxatag™: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Pharmacodynamics/Kinetics
Absorption: Oral: Rapid and nearly complete; food does not interfere
Extended-release tablet: Rate of absorption is slower compared to immediate-release formulations; food decreases the rate but not extent of absorption
Distribution: Widely to most body fluids and bone; poor penetration into cells, eyes, and across normal meninges
Pleural fluids, lungs, and peritoneal fluid; high urine concentrations are attained; also into synovial fluid, liver, prostate, muscle, and gallbladder; penetrates into middle ear effusions, maxillary sinus secretions, tonsils, sputum, and bronchial secretions
CSF:blood level ratio: Normal meninges: <1%; Inflamed meninges: 8% to 90%
Protein binding: 17% to 20%
Metabolism: Partially hepatic
Half-life elimination:
Neonates, full-term: 3.7 hours
Infants and Children: 1-2 hours
Adults: Normal renal function: 0.7-1.4 hours
Clcr <10 mL/minute: 7-21 hours
Time to peak: Capsule: 2 hours; Extended-release tablet: 3.1 hours; Suspension: 1 hour
Excretion: Urine (60% as unchanged drug); lower in neonates
Note: Extended-release tablets: In healthy volunteers, serum drug concentrations were below 0.25 mcg/mL and undetectable at 16 hours following dosing.
Dosage
Usual dosage range:
Children ≤3 months: Oral: 20-30 mg/kg/day divided every 12 hours
Children >3 months and <40 kg: Oral: 20-50 mg/kg/day in divided doses every 8-12 hours
Children ≥12 years: Oral: Extended-release tablet: 775 mg once daily
Adults: Oral: 250-500 mg every 8 hours or 500-875 mg twice daily
Extended-release tablet: 775 mg once daily
Indication-specific dosing:
Children >3 months and <40 kg: Oral:
Acute otitis media: 80-90 mg/kg/day divided every 12 hours
Anthrax exposure (CDC guidelines): Note: Postexposure prophylaxis only with documented susceptible organisms: 80 mg/kg/day in divided doses every 8 hours (maximum: 500 mg/dose)
Community-acquired pneumonia:
4 months to <5 years: 80-100 mg/kg/day divided every 8 hours
5-15 years: 100 mg/kg/day divided every 8 hours; Note: Treatment with a macrolide or doxycycline (if age >8 years) is preferred due to higher prevalence of atypical pathogens in this age group
Ear, nose, throat, genitourinary tract, or skin/skin structure infections:
Mild-to-moderate: 25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours
Severe: 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours
Tonsillitis and/or pharyngitis: Children ≥12 years: Extended-release tablet: 775 mg once daily
Lower respiratory tract infections: 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours
Lyme disease: 25-50 mg/kg/day divided every 8 hours (maximum: 500 mg)
Prophylaxis against infective endocarditis: 50 mg/kg 1 hour before procedure. Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.
Adults: Oral:
Anthrax exposure (CDC guidelines): Note: Postexposure prophylaxis in pregnant or nursing women only with documented susceptible organisms: 500 mg every 8 hours
Chlamydial infection during pregnancy (unlabeled use): 500 mg 3 times/day for 7 days (CDC, 2010)
Ear, nose, throat, genitourinary tract, or skin/skin structure infections:
Mild-to-moderate: 500 mg every 12 hours or 250 mg every 8 hours
Severe: 875 mg every 12 hours or 500 mg every 8 hours
Tonsillitis and/or pharyngitis: Extended-release tablet: 775 mg once daily
Helicobacter pylori
eradication: 1000 mg twice daily; requires combination therapy with at least one other antibiotic and an acid-suppressing agent (proton pump inhibitor or H2 blocker)
Lower respiratory tract infections: 875 mg every 12 hours or 500 mg every 8 hours
Lyme disease: 500 mg every 6-8 hours (depending on size of patient) for 21-30 days
Prophylaxis against infective endocarditis: 2 g 30-60 minutes before procedure. Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.
Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia: 2 g 1 hour prior to procedure
Dosing interval in renal impairment: Use of certain dosage forms (eg, extended-release 775 mg tablet and immediate-release 875 mg tablet) should be avoided in patients with Clcr <30 mL/minute or patients requiring hemodialysis.
Clcr 10-30 mL/minute: 250-500 mg every 12 hours
Clcr <10 mL/minute: 250-500 mg every 24 hours
Dialysis: Moderately dialyzable (20% to 50%) by hemo- or peritoneal dialysis; approximately 50 mg of amoxicillin per liter of filtrate is removed by continuous arteriovenous or venovenous hemofiltration; dose as per Clcr <10 mL/minute guidelines
Dental Usual Dosing
Oral:
Children >3 months and <40 kg: Prophylaxis against infective endocarditis: 50 mg/kg 30-60 minutes before procedure. Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.
Adults:
Prophylaxis against infective endocarditis: 2 g 30-60 minutes before procedure. Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.
Orofacial infection: 250-500 mg every 8 hours or 500-875 mg twice daily
Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia: 2 g 1 hour prior to procedure
Administration: Oral
Administer around-the-clock to promote less variation in peak and trough serum levels. The appropriate amount of suspension may be mixed with formula, milk, fruit juice, water, ginger ale, or cold drinks; administer dose immediately after mixing.
Moxatag™ extended release tablet: Administer within 1 hour of finishing a meal.
Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.
Monitoring Parameters
With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; assess patient at beginning and throughout therapy for infection; monitor for signs of anaphylaxis during first dose
Test Interactions
May interfere with urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest®)
Some penicillin derivatives may accelerate the degradation of aminoglycosides in vitro, leading to a potential underestimation of aminoglycoside serum concentration.
Dietary Considerations
May be taken with food.
Moxatag™: Take within 1 hour of finishing a meal.
Patient Education
Multiple daily doses should be taken at equal intervals around-the-clock. May be taken with milk, juice, or food. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause nausea, vomiting, or diarrhea. Report respiratory difficulty; rash, itching, or hives; easy bruising or bleeding; persistent diarrhea; signs of opportunistic infection (eg, unusual sore throat, fever, chills, fatigue, thrush, vaginal discharge); CNS changes (confusion, agitation, dizziness, insomnia); or if condition being treated worsens or does not improve by time prescription is completed.
Geriatric Considerations
Resistance to amoxicillin has been a problem in patients on frequent antibiotics or in nursing homes. Alternative antibiotics may be necessary in these populations. Consider renal function.
Cardiovascular Considerations
For the prevention of bacterial endocarditis in susceptible individuals, amoxicillin 2 g orally can be given 1 hour before, in the absence of a contraindication, for a dental, oral, respiratory tract, or esophageal procedure.
Dental Health: Effects on Dental Treatment
Prolonged use of penicillins may lead to development of oral candidiasis
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
No information available to require special precautions
Infectious Diseases Comment
A well-documented reaction can occur between beta-lactam and aminoglycoside antibiotics in vitro, leading to complexation, opening of the beta-lactam ring and presumably, loss of antibacterial activity for one or both agents. However, the conditions under which this reaction occurs are variable and influenced by (but not limited to) assay methodology, sampling time and storage, and drug selection and concentration. In general, many of the in vitro studies employed artificial conditions that tested high concentrations of the penicillin derivative (equating to serum levels most likely observed only in severe renal impairment) in combination with gentamicin or tobramycin. Incubation of the agents at conditions of 37°C for up to 48 hours has definitely demonstrated inactivation and loss of bactericidal activity. However, some of these studies permitted a considerable time lapse prior to assaying the medium, or stored the samples at higher temperatures (-20°C or greater), which may have allowed continued chemical degradation prior to assay. In general, amikacin was the most resistant to penicillin-mediated chemical degradation, and cephalosporins were much less likely than penicillins to inactivate the aminoglycosides.
The more robust studies have been those which evaluated in vivo effects via rapid and frequent blood sampling during concomitant dosing. In vivo, there are a number of studies documenting significant changes in the half-life of gentamicin in combination with primarily ticarcillin and carbenicillin, but usually only in the setting of end-stage renal disease. A number of literature reports suggest that despite documented changes in gentamicin kinetics, this is not likely to lead to clinically-significant differences in outcomes in patients with normal renal function. Furthermore, there are no published, prospective, outcome-based studies that provide compelling evidence of changes in rates of clinical or microbiological response as a function of dosing separation.
Based on the weight of evidence to date, coadministration of (but not coadmixture of) a penicillin or cephalosporin antibiotic with an aminoglycoside should not pose a significant concern in patients with even mild renal impairment. However, specific circumstances exist in which this approach should be undertaken with caution. Concurrent administration of either gentamicin or tobramycin with piperacillin, carbenicillin, or ticarcillin (including combinations with beta-lactamase inhibitors), particularly in the face of moderate-to-severe renal failure, would warrant careful monitoring of aminoglycoside serum levels, CBCs and clinical response to avoid potentially reduced efficacy due to chemical inactivation.
Note: Extended-release tablets: In healthy volunteers, serum drug concentrations were below 0.25 mcg/mL and undetectable at 16 hours following dosing. Currently, this formulation is only approved for use in patients with tonsillitis and/or pharyngitis secondary to S. pyogenes.
Mental Health: Effects on Mental Status
Rarely large doses may produce confusion, hallucinations, and depression; penicillins have been reported to cause apprehension, illusions, agitation, insomnia, depersonalization, and encephalopathy
Mental Health: Effects on Psychiatric Treatment
Disulfiram may increase amoxicillin levels
Nursing: Physical Assessment/Monitoring
Assess culture and sensitivity report and patient allergy history prior to starting therapy. Monitor for opportunistic infection.
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, oral: 250 mg, 500 mg
Powder for suspension, oral: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)
Tablet, oral: 500 mg, 875 mg
Tablet, chewable, oral: 125 mg, 200 mg, 250 mg, 400 mg
Tablet, extended release, oral:
Moxatag™: 775 mg
Pricing: U.S. (www.drugstore.com)
Capsules (Amoxicillin)
250 mg (90): $17.99
500 mg (30): $14.99
Chewable (Amoxicillin)
125 mg (21): $11.99
250 mg (30): $13.99
Suspension (reconstituted) (Amoxicillin)
250 mg/5 mL (150): $13.99
400 mg/5 mL (100): $16.99
Tablets (Amoxicillin)
500 mg (100): $49.99
875 mg (30): $26.99
References
American Academy of Pediatrics Committee on Drugs, "Transfer of Drugs and Other Chemicals Into Human Milk," Pediatrics, 2001, 108(3):776-89.
American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, “Diagnosis and Management of Acute Otitis Media,” Pediatrics, 2004, 113(5):1451-65.
Boguniewicz M and Leung DY, “Hypersensitivity Reactions to Antibiotics Commonly Used in Children,” Pediatr Infect Dis J, 1995, 14(3):221-31.
Bradley JS, “Management of Community-Acquired Pediatric Pneumonia in an Era of Increasing Antibiotic Resistance and Conjugate Vaccines,” Pediatr Infect Dis J, 2002, 21:592-8.
Canafax DM, Yuan Z, Chonmaitree T, et al, “Amoxicillin Middle Ear Fluid Penetration and Pharmacokinetics in Children With Acute Otitis Media,” Pediatr Infect Dis J, 1998, 17(2):149-56.
Centers for Disease Control and Prevention (CDC), "Sexually Transmitted Diseases Treatment Guidelines, 2010," MMWR Recomm Rep, 2010, 59(RR-12):1-110.
Chey WD and Wong B, “American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection,” Am J Gastroenterol, 2007 102(8):1808-25.
Chow MS, Quintiliani R, and Nightingale CH, “In Vivo Inactivation of Tobramycin by Ticarcillin. A Case Report,” JAMA, 1982, 247(5):658-9.
Dajani AS, Taubert KA, Wilson WW, et al, “Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,” JAMA, 1997, 277(22):1794-801.
Daly JS, Dodge RA, Glew RH, et al, “Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages," J Perinatol, 1997, 17(1):42-5.
Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med, 1988, 318(7):419-26 and 318(8):490-500.
Dougall HT, Smith L, Duncan C, et al, “The Effect of Amoxicillin on Salivary Nitrite Concentrations: An Important Mechanism of Adverse Reactions?” Br J Clin Pharmacol, 1995, 39(4):460-2.
Dowell JA, Korth-Bradley J, Milisci M, et al, “Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,” J Clin Pharmacol, 2001, 41:979-86.
Farchione LA, “Inactivation of Aminoglycosides by Penicillins,” J Antimicrob Chemother, 1982, 8(Suppl A):27-36.
Fuchs PC, Stickel S, Anderson PH, et al, “In Vitro Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,” Antimicrob Agents Chemother, 1991, 35(1):182-4.
Halstenson CE, Wong MO, Herman CS, et al, “Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,” Antimicrob Agents Chemother, 1992, 36(9):1832-36.
Hautekeete ML, Brenard R, Horsmans Y, et al, “Liver Injury Related to Amoxycillin-Clavulanic Acid: Interlobular Bile-Duct Lesions and Extrahepatic Manifestations,” J Hepatol, 1995, 22(1):71-7.
Hill S, Yeates M, Pathy J, et al, “A Controlled Trial of Norfloxacin and Amoxicillin in the Treatment of Uncomplicated Urinary Tract Infection in the Elderly,” J Antimicrob Chemother, 1985, 15(4):505-6.
Hitt CM, Patel KB, Nicolau DP, et al, “Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,” Am J Health Syst Pharm, 1997, 54(23):2704-8.
Jones KH and Hill SA, “The Toxicology, Absorption and Pharmacokinetics of Amoxicillin,” Adv Clin Pharmacol, 1974, 7:20.
Konishi H, Goto M, Nakamoto Y, et al, “Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,” Antimicrob Agents Chemother, 1983, 23(5):653-57.
Korppi M, “Community-Acquired Pneumonia in Children. Issues in Optimizing Antibacterial Treatment,” Pediatr Drugs, 2003, 5(12):821-32.
Lau A, Lee M, Flascha S, et al, “Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,” Antimicrob Agents Chemother, 1983, 24(4):533-37.
McIntosh K, “Community-Acquired Pneumonia in Children,” N Engl J Med, 2002, 346(6):429-37.
Oe PL, Simonian S, Verhoef J, “Pharmacokinetics of the New Penicillins, Amoxicillin and Flucloxacillin in Patients With Terminal Renal Failure Undergoing Hemodialysis,” Chemotherapy, 1973, 19:279.
Parry MF, “The Penicillins,” Med Clin North Am, 1987, 71(6):1093-112.
Prignet JM, Galzin M, Duval JL, et al, “Amoxicillin-Induced Esophageal Ulcer With Intractable Hiccups as the Presenting Manifestation,” Sem Hop, 1995, 71:186-7.
Russoe ME and Atkins-Thor E, “Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,” Clin Nephrol, 1981, 15(4):175-80.
Swanson-Biearman B, Dean DS, Lopez G, et al, “The Effects of Penicillin and Cephalosporin Ingestions in Children Less Than Six Years of Age,” Vet Hum Toxicol, 1988, 30(1):66-7.
Talley NJ and Vakil N, “Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,” Am J Gastroenterol, 2005, 100(10):2324-37.
Thompson MIB, Russo ME, Saxon BJ, et al, “Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,” Antimicrob Agents Chemother, 1982, 21(2):268-73.
Tu YH, Stiles ML, Allen LV Jr, et al, "Stability of Amoxicillin Trihydrate-Potassium Clavulanate in Original Containers and Unit Dose Oral Syringes," Am J Hosp Pharm, 1988, 45(5):1092-9.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, “Commentary on Nonlabeled Dosing of Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax,” December 10, 2001. Available at http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm
Viollier AF, Standiford HC, Drusano GL, et al, “Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,” J Antimicrob Chemother, 1985, 15(5):597-606.
Walterspiel JN, Feldman S, Van R, et al, “Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,” Antimicrob Agents Chemother, 1991, 35(9):1875-8.
Westphal JF, Jehl F, Brogard JM, et al, “Amoxicillin Intestinal Absorption Reduction by Amiloride: Possible Role of the Na+-H+ Exchanger,” Clin Pharmacol Ther, 1995, 57(3):257-64.
Wilson W, Taubert KA, Gewitz M, et al, “Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,” Circulation, 2007, 115.
Wright AJ, “The Penicillins,” Mayo Clin Proc, 1999, 74(3):290-307.
Wynn RL, “Amoxicillin Update,” Gen Dent, 1991, 39(5):322,4,6.
International Brand Names
Lexi-Comp.com
Last full review/revision May 2011
Content last modified May 2011
| 
